摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

2-formyl-pent-4-enoic acid | 5735-65-9

中文名称
——
中文别名
——
英文名称
2-formyl-pent-4-enoic acid
英文别名
2-Formyl-pent-4-ensaeure;2-Formylpent-4-enoic acid
2-formyl-pent-4-enoic acid化学式
CAS
5735-65-9
化学式
C6H8O3
mdl
MFCD19230202
分子量
128.128
InChiKey
FCCFILBFLFEAOM-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    0.6
  • 重原子数:
    9
  • 可旋转键数:
    4
  • 环数:
    0.0
  • sp3杂化的碳原子比例:
    0.333
  • 拓扑面积:
    54.4
  • 氢给体数:
    1
  • 氢受体数:
    3

反应信息

  • 作为产物:
    描述:
    alkaline earth salt of/the/ methylsulfuric acid 在 sodium hydroxide 作用下, 生成 2-formyl-pent-4-enoic acid
    参考文献:
    名称:
    Allylic rearrangement
    摘要:
    公开号:
    US02540071A1
点击查看最新优质反应信息

文献信息

  • [EN] NOVEL ANTI-BIOFILM AGENTS<br/>[FR] NOUVEAUX AGENTS ANTI-BIOFILMS
    申请人:YISSUM RES DEV CO
    公开号:WO2010058402A1
    公开(公告)日:2010-05-27
    Novel agents exhibiting anti-biofilm formation activity while being non-cytotoxic are provided, as well as methods of using the same, either per se or conjugated to a polymer, for preventing and/or reducing the formation of microbial biofilms and/or for disrupting microbial biofilms. The novel agents described herein include thiazolidine-2,4-diones (TZDs), pyrrolidine -2, 5- diones (PYDs), imidazolidine-2, 4 -diones or oxazolidine-2,4-diones, substituted by an alkylidene having 7-20 carbon atoms in its backbone chain.
    提供了一种表现出抗生物膜形成活性且无细胞毒性的新型药剂,以及使用这些药剂的方法,可以直接使用或与聚合物结合,用于预防和/或减少微生物生物膜的形成和/或破坏微生物生物膜。本文描述的新型药剂包括噻唑烷-2,4-二酮(TZDs)、吡咯烷-2,5-二酮(PYDs)、咪唑烷-2,4-二酮或噁唑烷-2,4-二酮,其通过具有7-20个碳原子的烷基烯链进行取代。
  • NOVEL ANTI-BIOFILM AGENTS
    申请人:Srebnik Morris
    公开号:US20110281921A1
    公开(公告)日:2011-11-17
    Novel agents exhibiting anti-biofilm formation activity while being non-cytotoxic are provided, as well as methods of using the same, either per se or conjugated to a polymer, for preventing and/or reducing the formation of microbial biofilms and/or for disrupting microbial biofilms. The novel agents described herein include thiazolidine-2,4-diones (TZDs), pyrrolidine-2,5-diones (PYDs), imidazolidine-2,4-diones or oxazolidine-2,4-diones, substituted by an alkyl having 7-20 carbon atoms in its backbone chain.
    本发明提供了一种表现出抗生物膜形成活性且非细胞毒性的新型药剂,以及使用它们的方法,无论是自身还是与聚合物结合,用于预防和/或减少微生物生物膜的形成和/或破坏微生物生物膜。本发明所描述的新型药剂包括噻唑啉-2,4-二酮(TZDs)、吡咯烷-2,5-二酮(PYDs)、咪唑啉-2,4-二酮或噁唑啉-2,4-二酮,其被一个含有7-20个碳原子的烷基取代。
  • 1,3-Dioxan-5-ylalkenoic acids
    申请人:IMPERIAL CHEMICAL INDUSTRIES PLC
    公开号:EP0094239A2
    公开(公告)日:1983-11-16
    he invention concerns novel 4-phenyl-1,3-dioxan -5-ylalkenoic acid derivatives of the formula I having is relative stereochemistry at positions 4 and 5 of the dioxane ring and wherein Ra and Rb are variously hydrogen, alkyl, halogenoalkyl, alkenyl, and optionally substituted aryl or arylalkyl, Rc is hydroxy, alkoxy or alkanesulphonamido, n is 1 or 2, A is ethylene or vinylene, Y is (2-5C)polymethylene optionally substituted by alkyl, and benzene ring B is optionally substituted phenyl, or, when Rc is hydroxy, a salt thereof. The acid derivatives antagonise one or more of the actions of thromboxane A2 (TXA2) and are expected to be of value in those disease conditions in which TXA2 is involved. The invention also provides pharmaceutical compositions containing an acid derivative of formula 1, and processes for their chemical production.
    本发明涉及式 I 的新型 4-苯基-1,3-二噁烷-5-基烯酸衍生物,其二噁烷环的第 4 位和第 5 位具有相对立体化学结构,其中 Ra 和 Rb 分别为氢、烷基、卤代烷基、烯基和任选取代的芳基或芳烷基,Rc 为羟基、烷氧基或烷磺酰胺基,n 为 1 或 2,A 为乙烯乙烯基,Y 为(1,3-二噁烷-5-基烯酸)、和任选取代的芳基或芳烷基,Rc 是羟基、烷氧基或烷磺酰胺基,n 是 1 或 2,A 是乙烯乙烯基,Y 是任选被烷基取代的(2-5C)聚亚甲基,苯环 B 是任选取代的苯基,或当 Rc 是羟基时,是其盐。这些酸衍生物可拮抗血栓素 A2(TXA2)的一种或多种作用,因此有望在涉及 TXA2 的疾病中发挥重要作用。本发明还提供了含有式 1 酸衍生物的药物组合物及其化学生产工艺。
  • Continuous hydrogenation process
    申请人:F. HOFFMANN-LA ROCHE AG
    公开号:EP1063224A1
    公开(公告)日:2000-12-27
    The invention relates to a continuous process for enantioselective catalytic hydrogenation of an alpha ketocarbonyl compound such as alpha ketoesters and alpha ketolactones to produce an alpha hydroxy carbonyl compound.
    本发明涉及一种对映体选择性催化α-酮羰基化合物(如α-酮酯和α-酮内酯)加氢生成α-羟基羰基化合物的连续工艺。
  • Novel anti-biofilm agents
    申请人:Yissum Research Development Company of The Hebrew University of Jerusalem Ltd.
    公开号:EP2365969B1
    公开(公告)日:2017-03-22
查看更多